Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;20(9):1100-1109.
doi: 10.1038/s41590-019-0433-y. Epub 2019 Jul 29.

Mechanisms of immunotherapy resistance: lessons from glioblastoma

Christopher M Jackson  1 , John Choi  1 , Michael Lim  2
Affiliations
Review

Mechanisms of immunotherapy resistance: lessons from glioblastoma

Christopher M Jackson et al. Nat Immunol. 2019 Sep.

Abstract

Glioblastoma (GBM) is the deadliest form of brain cancer, with a median survival of less than 2 years despite surgical resection, radiation, and chemotherapy. GBM's rapid progression, resistance to therapy, and inexorable recurrence have been attributed to several factors, including its rapid growth rate, its molecular heterogeneity, its propensity to infiltrate vital brain structures, the regenerative capacity of treatment-resistant cancer stem cells, and challenges in achieving high concentrations of chemotherapeutic agents in the central nervous system. Escape from immunosurveillance is increasingly recognized as a landmark event in cancer biology. Translation of this framework to clinical oncology has positioned immunotherapy as a pillar of cancer treatment. Amid the bourgeoning successes of cancer immunotherapy, GBM has emerged as a model of resistance to immunotherapy. Here we review the mechanisms of immunotherapy resistance in GBM and discuss how insights into GBM-immune system interactions might inform the next generation of immunotherapeutics for GBM and other resistant pathologies.

PubMed Disclaimer

References

    1. Nachman, M. W. & Crowell, S. L. Estimate of the mutation rate per nucleotide in humans. Genetics 156, 297–304 (2000). - PubMed - PMC
    1. Vogelstein, B. et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med. 319, 525–532 (1988). - PubMed
    1. Hastings, K. G. et al. Socioeconomic differences in the epidemiologic transition from heart disease to cancer as the leading cause of death in the United States, 2003 to 2015: an observational study. Ann. Intern. Med. 169, 836–844 (2018). - PubMed
    1. Ribatti, D. The concept of immune surveillance against tumors. The first theories. Oncotarget 8, 7175–7180 (2017). - PubMed
    1. Dunn, G. P., Old, L. J. & Schreiber, R. D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329–360 (2004). This review (ref. 5) describes the interactions between a tumor and the immune system that govern tumor progression or clearance. This framework is important for understanding how tumors respond to immunological pressure. - PubMed

LinkOut - more resources